info@epichembio.eu + 34 986 812 316

Fraunhofer-IME SP. Molecular Biology. ScreeningPort

Sheraz.Gul@ime.fraunhofer.de
www.ime.fraunhofer.de/en/businessareasMB/screeningport.html
Address
Schnackenburgallee 114, D-22525 Hamburg, Germany
Germany
Keywords

Assay Development, High Throughput Screening, HDAC, High Content Screening, Translational Research.

Models

Target-based assays, cell-based assays.

Techniques

The Fraunhofer IME-SP has access to industry standard assay development and High Throughput Screening equipment, small molecule libraries up to 500,000 compounds, PerkinElmer Opera High Content Imaging System, PerkinElmer EnVision multifunction reader and in-silico approaches to identify compounds that are potentially capable of modulating target activity.

Collaborations outside COST

The Fraunhofer IME-SP use its assets in a variety of FP7, Innovative Medicines Initiative, COST Action and other funded projects across Europe to perform assay, development, High Throughput Screening, ADME-Tox assays to progress compounds to the Lead stage in drug discovery. The outputs of this work has included various publications and a patent application on a novel kinase assay.

Short description of ongoing research projects

The Fraunhofer is Europe’s largest application-oriented research organization and the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) - ScreeningPort Division acts as a platform between basic research and industrial development with specific focus along the drug discovery and development value chain. The implementation of this approach allows the Fraunhofer IME-SP to pursue innovative targets and advance their development, thus substantially contributing to applied drug research in Europe. Current projects include: 2012-2017: Innovative Medicines Initiative, Kinetics for Drug Discovery (K4DD). 2012-2017: Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population (EuRhythDia). FP7 project. 2013-2016: Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention (CVgenes@target). FP7 project. 2013-2016: New Medicines for Trypanosomatidic Infections (NMTrypI). FP7 project. 2013-2017: Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases (PDE4NPD). FP7 project. 2014-2017: COST Action, Targeted chemotherapy towards diseases caused by endoparasites. 2014-2016: Innovative Medicines Initiative, European Bank for induced pluripotent Stem Cells (EBiSC).

Publications
  1. Development of an insect-cell-based assay for detection of kinase inhibition using NF-kB inducing kinase as a paradigm. Hassan, N., Gul, S., Flett, F., Hollingsworth, E., Dunne, A., Emmons, A.J., Hutchinson, J., Hibbs, M., Tew, D., Powell, D.J. & Morse, M., Biochemical Journal, 2009, 419, 65-73.
  2. A bioluminogenic HDAC activity assay - validation and screening. Halley, F., Reinshagen, J., Wolf, M., Niles, A. L., Evans, N. J., Wagner, J. M., Jung, M., Gribbon, P. & Gul, S. Journal of Biomolecular Screening, 2011, 16, 1227-1235.
  3. Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair. Bushman, J., Mishra, B., Ezra, M., Gul, S., Schulze, C., Chaudhury, S., Ripoll, D., Wallqvist, A., Kohn, J., Schachner, M. & Loers, G. Neuropharmacology, 2014, 79, 456-466.
  4. Protein–protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low and high throughput screening compatible assays. Gul, S. & Hadian, K. Expert Opinion On Drug Discovery, 2014, 9, 1393-1404.
  5. Identification of 2-[4-[(4-methoxyphenyl)methoxy]-phenyl]acetonitrile (O4I1) and derivatives as potent Oct3/4 inducers. Cheng, X., Dimou, E., Alborzinia, H., Wenke, F., Göhring, A., Reuter, S., Mah, N., Fuchs, H., Andrade-Navarro, M.A., Adjaye, J., Gul, S., Harms, C., Utikal, J., Klipp, E., Mrowka, R. & Wölfl, S. Journal of Medicinal Chemistry, 2015, 58, 4976-4983.
Other activities of potential interest to others

The Fraunhofer IME-SP provides training (theoretical and laboratory based) as exemplified by the “From Target to Lead Compound: Assay Development, Screening and Hit-to-Lead compound optimisation” run on 28-09-2015 to 01-10-2015 in Hamburg as a Training School for the COST Action CM1307 on “Targeted chemotherapy towards diseases caused by endoparasites”. See http://www.costcm1307.org/CM1307/Training_Schools.html. The Fraunhofer IME-SP have 9 such events in Hamburg, Brazil and Saudi Arabia.


Cost UE